Immutep leaps on reporting positive TACTI-002 data

19 February 2020

Australian biotech firm Immutep (ASX: IMM) today announced positive interim data from its ongoing Phase II TACTI-002 study, news of which pushed its share up 14.1% to A$0.44 by close of trading.

The results were presented today at the 34th German Cancer Congress in Berlin by principal investigator, Dr Bernhard Doger of START Madrid, Spain.

The data relates to use of the company’s lead product candidate eftilagimod alpha (efti or IMP321), a soluble LAG-3 protein, as part of a combination treatment with pembrolizumab, Merck & Co’s blockbuster immune-oncology drug Keytruda. The activation of antigen-presenting cells (APC) and subsequent T cell recruitment with efti may lead to stronger anti-tumor responses than observed with pembrolizumab alone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK